- Home
- SPPL vs AEON Comparison
SPPL vs AEON Comparison
Compare SPPL & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPL
- AEON
- Stock Information
- Founded
- SPPL 2016
- AEON N/A
- Country
- SPPL Singapore
- AEON United States
- Employees
- SPPL N/A
- AEON N/A
- Industry
- SPPL
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- SPPL
- AEON Health Care
- Exchange
- SPPL Nasdaq
- AEON Nasdaq
- Market Cap
- SPPL 9.8M
- AEON 8.0M
- IPO Year
- SPPL 2023
- AEON N/A
- Fundamental
- Price
- SPPL $6.00
- AEON $1.13
- Analyst Decision
- SPPL
- AEON Strong Buy
- Analyst Count
- SPPL 0
- AEON 1
- Target Price
- SPPL N/A
- AEON $7.20
- AVG Volume (30 Days)
- SPPL 14.0K
- AEON 370.8K
- Earning Date
- SPPL 01-01-0001
- AEON 11-12-2025
- Dividend Yield
- SPPL N/A
- AEON N/A
- EPS Growth
- SPPL N/A
- AEON N/A
- EPS
- SPPL N/A
- AEON N/A
- Revenue
- SPPL $4,591,508.00
- AEON N/A
- Revenue This Year
- SPPL N/A
- AEON N/A
- Revenue Next Year
- SPPL N/A
- AEON N/A
- P/E Ratio
- SPPL N/A
- AEON N/A
- Revenue Growth
- SPPL 24.27
- AEON N/A
- 52 Week Low
- SPPL $2.16
- AEON $0.38
- 52 Week High
- SPPL $16.80
- AEON $83.52
- Technical
- Relative Strength Index (RSI)
- SPPL 58.28
- AEON 58.41
- Support Level
- SPPL $5.33
- AEON $1.03
- Resistance Level
- SPPL $7.00
- AEON $1.41
- Average True Range (ATR)
- SPPL 0.41
- AEON 0.14
- MACD
- SPPL -0.06
- AEON 0.02
- Stochastic Oscillator
- SPPL 43.69
- AEON 53.35
About SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.